Physician profile
Robert Palguta
NPI 1841240660
$1,060.07
in general payments reported to CMS, 2019-2025
23 companies · $86.23 in 2025
The $86.23 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2021: $19.60 · 2022: $42.74 · 2024: $122 · 2025: $86.23.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $123 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $123.19 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $174.43 | 2019 | |
| Amarin Pharma, INC. | $90.18 | 2019 | |
| Medtronic, INC. | $86.23 | 2025 | Inceptiv |
| Astellas Pharma US INC | $84.99 | 2024 | |
| Glaxosmithkline, LLC. | $77.66 | 2019 | |
| Lilly USA, LLC | $75.21 | 2019 | |
| Amgen INC. | $71.02 | 2019-2024 | Prolia, Evenity |
| Janssen Pharmaceuticals, INC | $58.34 | 2019 | |
| Novo Nordisk INC | $57.65 | 2019 | |
| Abbvie INC. | $44.19 | 2019 | |
| Heartflow, INC. | $42.74 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.12 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $22.53 | 2019 | |
| Antares Pharma, INC. | $20.87 | 2019 | |
| Allergan, INC. | $19.75 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $19.60 | 2021 | |
| Avanir Pharmaceuticals, INC. | $15.66 | 2019 | |
| Merck Sharp & Dohme LLC | $14.84 | 2019 | |
| Horizon Therapeutics Plc | $14.08 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.80 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $11.41 | 2019 | |
| Abbott Laboratories | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Palguta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.